Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021366 citationsJournal Article

Authors

Peter Hillmen · Peter MacCallum Cancer Centre

Jeff Szer · The Royal Melbourne Hospital

Ilene C. Weitz · Peter MacCallum Cancer Centre

Alexander Röth · Peter MacCallum Cancer Centre

Britta Höchsmann · University Hospital Ulm

Jens Panse · RWTH Aachen University

Kensuke Usuki ·

Abstract

Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.).

Topics & Keywords

Complement system in diseases Adenosine and Purinergic Signaling Coagulation, Bradykinin, Polyphosphates, and Angioedema

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 11, pp. 1028-1037

DOI: 10.1056/nejmoa2029073

Field-Weighted Citation Impact: 21.53